SCHEMBL22989898

SCHEMBL22989898

COc1ccc(COc2cccc(F)c2NNC(=O)OC(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
PPARG P37231 2/20 0.41
PPARD Q03181 2/20 0.41
PPARA Q07869 2/20 0.41
PTPN1 P18031 1/20 0.41
SMPD1 P17405 1/20 0.41
GAA P10253 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
CACNA1B Q00975 1/20 0.40
FFAR1 O14842 1/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2894833 0.78 NPC1 (0.50) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL30800458 0.73 MAOB (0.53) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL4939083 0.73 MAOB (0.53) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL31562845 0.72 CACNA1B (0.41) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL7140411 0.72 HDAC1 (0.46) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL14908404 0.71 KMT2A (0.49) NPC1KMT2AMEN1KDM4EGAA
SCHEMBL8407940 0.70 NPC1 (0.54) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL4365909 0.70 PTGS2 (0.54) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL22989897 0.69 MAOB (0.51) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL2493016 0.69 NPC1 (0.49) NPC1RAB9AKMT2AMEN1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021027943-A1 PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF 正大天晴药业集团南京顺欣制药有限公司 2021-02-18 WO disclosed